Table 1 Baseline patients characteristics
Characteristic |  | N = 120 |
|---|---|---|
Age | Median (range) | 57.5 (29.0–75.0) |
|  | ≥ 65 | 35 (29.2) |
|  | < 65 | 85 (70.8) |
Sex, n (%) | Male | 49 (40.8) |
| Â | Female | 71 (59.2) |
ECOG PS, n (%) | 0 | 24 (20.0) |
| Â | 1 | 96 (80.0) |
Smoking history, n (%) | Never smoker | 89 (74.2) |
| Â | Former smoker | 27 (22.5) |
| Â | Current smoker | 4 (3.3) |
Histologic type, n (%) | Adenocarcinoma | 116 (96.7) |
| Â | Other | 4 (3.3) |
EGFR mutation type, n (%) | 19del | 65 (54.2) |
| Â | L858R | 52 (43.3) |
| Â | Other | 3 (2.5) |
Brain metastases, n (%) | Yes | 22 (18.3) |
| Â | No | 98 (81.7) |
Previous EGFR-TKIs treatment, n (%) | 1st /2nd | 86 (71.7) |
| Â | 3rd | 32 (26.7) |
| Â | 1st and 3rd | 1 (0.8) |
| Â | 2nd and 3rd | 1 (0.8) |
Previous EGFR-TKIs response, n (%) | PR | 56 (46.7) |
| Â | SD | 43 (35.8) |
| Â | NE | 18 (15.0) |
| Â | NA | 3 (2.5) |
EGFR-TKIs progression modes, n (%) | Gradual progression | 109 (90.8) |
| Â | Oligo progression | 6 (5.0) |
| Â | Potential progression | 5 (4.2) |